0001193125-17-128790.txt : 20170419 0001193125-17-128790.hdr.sgml : 20170419 20170419161055 ACCESSION NUMBER: 0001193125-17-128790 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170419 DATE AS OF CHANGE: 20170419 EFFECTIVENESS DATE: 20170419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 17770093 BUSINESS ADDRESS: STREET 1: 7999 GATEWAY BLVD STREET 2: SUITE 130 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7999 GATEWAY BLVD STREET 2: SUITE 130 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 DEFA14A 1 d156102ddefa14a.htm NOTICE & ACCESS Notice & Access

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

☐   Preliminary Proxy Statement
☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐   Definitive Proxy Statement
☒   Definitive Additional Materials
☐   Soliciting Material Pursuant to § 240.14a-12

CYMABAY THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

☒   No fee required.
☐   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  1.  

Title of each class of securities to which transaction applies:

 

     

  2.  

Aggregate number of securities to which transaction applies:

 

     

  3.  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  4.  

Proposed maximum aggregate value of transaction:

 

     

  5.  

Total fee paid:

 

     

☐   Fee paid previously with preliminary materials.
☐   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  6.  

Amount Previously Paid:

 

     

  7.  

Form, Schedule or Registration Statement No.:

 

     

  8.  

Filing Party:

 

     

  9.  

Date Filed:

 

     

 

 

 

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders of

CYMABAY THERAPEUTICS, INC.

To Be Held On:

Thursday, June 1, 2017, at 9:00 am Pacific Time

Pacific Research Center, 7677 Gateway Blvd. Conference Center 2nd Floor, Apex Room, Newark, CA 94560

 

 

COMPANY NUMBER  

 

    

 

ACCOUNT NUMBER  

 

    

 

CONTROL NUMBER  

 

    

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery, please make the request as instructed below before May 22, 2017.

Please visit http://www.astproxyportal.com/ast/18519/, where the following materials are available for view:

 

   •   Notice of Annual Meeting of Stockholders
   •   Proxy Statement
   •   Form of Electronic Proxy Card
   •   Annual Report on Form 10-K
TO REQUEST MATERIAL:    TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers)
   E-MAIL: info@astfinancial.com
   WEBSITE: https://us.astfinancial.com/proxyservices/requestmaterials.asp
TO VOTE:    ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date.
   IN PERSON: You may vote your shares in person by attending the Annual Meeting. Directions can be found at http://www.pacificresearchcenter.com or by contacting our Investor Relations at (510) 293-8121.
   TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. You may vote by telephone until 11:59 PM Eastern Time the day before the meeting.
   MAIL: You may request a card by following the instructions above.

 

 

1.     To elect the CymaBay Therapeutics, Inc. Board of Directors’ nine nominees as directors to serve until the 2018 Annual Meeting of Stockholders and until their successors are duly elected and qualified:

   

 

2.     To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of CymaBay Therapeutics, Inc. for its fiscal year ending December 31, 2017.

 

        NOMINEES:

   THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF DIRECTORS AND “FOR” PROPOSAL 2.

         Sujal A. Shah

   

         Robert F. Booth, Ph.D.

   

         Carl Goldfischer, M.D.

   

         Caroline Loewy

   

         Evan A. Stein, M.D., Ph.D.

   

         Paul F. Truex

   

         Kurt von Emster

   

         Robert J. Weiland

   

         Robert J. Wills, Ph.D.

   
 

 

Please note that you cannot use this notice to vote by mail.